drugset
drugset / Trial / NCT07304258

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

NCT07304258 ↗

Phase 2 Not yet recruiting 30 enrolled Hebei Medical University
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of HIPEC combined with NIPS and tislelizumab conversion therapy for gastric/gastroesophageal junction cancer with positive cytology alone (CY1P0) or a Peritoneal Carcinomatosis Index (PCI) ≤10

Timeline

Start
2025-12-12
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 20 mg/m2 Other
Subject Paclitaxel Small molecule 50 mg/m2 Other
Subject Paclitaxel Small molecule 75 mg/m2 Other
Subject S-1 Small molecule 40 mg Oral
Subject S-1 Small molecule 50 mg Oral
Subject S-1 Small molecule 60 mg Oral
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

peritoneal carcinomatosis